136 related articles for article (PubMed ID: 16287080)
1. Expression profiling of Wilms tumors reveals new candidate genes for different clinical parameters.
Zirn B; Hartmann O; Samans B; Krause M; Wittmann S; Mertens F; Graf N; Eilers M; Gessler M
Int J Cancer; 2006 Apr; 118(8):1954-62. PubMed ID: 16287080
[TBL] [Abstract][Full Text] [Related]
2. All-trans retinoic acid treatment of Wilms tumor cells reverses expression of genes associated with high risk and relapse in vivo.
Zirn B; Samans B; Spangenberg C; Graf N; Eilers M; Gessler M
Oncogene; 2005 Aug; 24(33):5246-51. PubMed ID: 15897880
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profiling of favorable histology Wilms tumors and its correlation with clinical features.
Takahashi M; Yang XJ; Lavery TT; Furge KA; Williams BO; Tretiakova M; Montag A; Vogelzang NJ; Re GG; Garvin AJ; Söderhäll S; Kagawa S; Hazel-Martin D; Nordenskjold A; Teh BT
Cancer Res; 2002 Nov; 62(22):6598-605. PubMed ID: 12438255
[TBL] [Abstract][Full Text] [Related]
4. Retinoic acid pathway activity in Wilms tumors and characterization of biological responses in vitro.
Wegert J; Bausenwein S; Kneitz S; Roth S; Graf N; Geissinger E; Gessler M
Mol Cancer; 2011 Nov; 10():136. PubMed ID: 22067876
[TBL] [Abstract][Full Text] [Related]
5. A gene expression signature for relapse of primary wilms tumors.
Li W; Kessler P; Yeger H; Alami J; Reeve AE; Heathcott R; Skeen J; Williams BR
Cancer Res; 2005 Apr; 65(7):2592-601. PubMed ID: 15805255
[TBL] [Abstract][Full Text] [Related]
6. Expression profiling reveals MSX1 and EphB2 expression correlates with the invasion capacity of Wilms tumors.
Chetcuti A; Aktas S; Mackie N; Ulger C; Toruner G; Alkan M; Catchpoole D
Pediatr Blood Cancer; 2011 Dec; 57(6):950-7. PubMed ID: 21387540
[TBL] [Abstract][Full Text] [Related]
7. New prognostic markers revealed by evaluation of genes correlated with clinical parameters in Wilms tumors.
Wittmann S; Wunder C; Zirn B; Furtwängler R; Wegert J; Graf N; Gessler M
Genes Chromosomes Cancer; 2008 May; 47(5):386-95. PubMed ID: 18260125
[TBL] [Abstract][Full Text] [Related]
8. Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms Tumor.
Reinhard H; Semler O; Bürger D; Bode U; Flentje M; Göbel U; Gutjahr P; Leuschner I; Maass E; Niggli F; Scheel-Walter HG; Stöckle M; Thüroff JW; Tröger J; Weirich A; von Schweinitz D; Zoubek A; Graf N
Klin Padiatr; 2004; 216(3):132-40. PubMed ID: 15175957
[TBL] [Abstract][Full Text] [Related]
9. Geometry of Gene Expression Space of Wilms' Tumors From Human Patients.
Trink A; Kanter I; Pode-Shakked N; Urbach A; Dekel B; Kalisky T
Neoplasia; 2018 Aug; 20(8):871-881. PubMed ID: 30029183
[TBL] [Abstract][Full Text] [Related]
10. [Wilms' tumor: reached progress and future prospects].
Tamaro P
Arch Ital Urol Androl; 1997 Sep; 69(4):227-32. PubMed ID: 9417294
[TBL] [Abstract][Full Text] [Related]
11. Transcript profiling of Wilms tumors reveals connections to kidney morphogenesis and expression patterns associated with anaplasia.
Li W; Kessler P; Williams BR
Oncogene; 2005 Jan; 24(3):457-68. PubMed ID: 15531917
[TBL] [Abstract][Full Text] [Related]
12. The role of TCF3 as potential master regulator in blastemal Wilms tumors.
Kehl T; Schneider L; Kattler K; Stöckel D; Wegert J; Gerstner N; Ludwig N; Distler U; Tenzer S; Gessler M; Walter J; Keller A; Graf N; Meese E; Lenhof HP
Int J Cancer; 2019 Mar; 144(6):1432-1443. PubMed ID: 30155889
[TBL] [Abstract][Full Text] [Related]
13. 16q heterozygosity loss in Wilms' tumour in children and its clinical importance.
Skotnicka-Klonowicz G; Rieske P; Bartkowiak J; Szymik-Kantorowicz S; Daszkiewicz P; Debiec-Rychter M
Eur J Surg Oncol; 2000 Feb; 26(1):61-6. PubMed ID: 10718182
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of c-MYC in WT1-mutant tumors: assessment of WT1 putative transcriptional targets using cDNA microarray expression profiling of genetically defined Wilms' tumors.
Udtha M; Lee SJ; Alam R; Coombes K; Huff V
Oncogene; 2003 Jun; 22(24):3821-6. PubMed ID: 12802290
[TBL] [Abstract][Full Text] [Related]
15. Decreased E-cadherin expression correlates with higher stage of Wilms' tumors.
Safford SD; Freemerman AJ; Langdon S; Bentley R; Goyeau D; Grundy PE; Skinner MA
J Pediatr Surg; 2005 Feb; 40(2):341-8. PubMed ID: 15750927
[TBL] [Abstract][Full Text] [Related]
16. Changes in WT1 splicing are associated with a specific gene expression profile in Wilms' tumour.
Baudry D; Faussillon M; Cabanis MO; Rigolet M; Zucker JM; Patte C; Sarnacki S; Boccon-Gibod L; Junien C; Jeanpierre C
Oncogene; 2002 Aug; 21(36):5566-73. PubMed ID: 12165855
[TBL] [Abstract][Full Text] [Related]
17. Profiling of differential gene expression in Wilms tumor by cDNA expression array.
Rigolet M; Faussillon M; Baudry D; Junien C; Jeanpierre C
Pediatr Nephrol; 2001 Dec; 16(12):1113-21. PubMed ID: 11793111
[TBL] [Abstract][Full Text] [Related]
18. Wilms tumour histology is determined by distinct types of precursor lesions and not epigenetic changes.
Fukuzawa R; Anaka MR; Heathcott RW; McNoe LA; Morison IM; Perlman EJ; Reeve AE
J Pathol; 2008 Aug; 215(4):377-87. PubMed ID: 18484682
[TBL] [Abstract][Full Text] [Related]
19. Association of E2F3 expression with clinicopathological features of Wilms' tumors.
An Q; Wang Y; An R; Li Y; Yao T; Zhai B; Sun X
J Pediatr Surg; 2013 Nov; 48(11):2187-93. PubMed ID: 24210184
[TBL] [Abstract][Full Text] [Related]
20. Intra-tumor genetic heterogeneity in Wilms tumor samples.
de Sá Pereira BM; Azevedo RM; Aguirre Neto JC; Menezes CF; Rodrigues KE; Faria PA; Camargo B; Maschietto M
Rev Assoc Med Bras (1992); 2019 Dec; 65(12):1496-1501. PubMed ID: 31994632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
